Sepsis Clinical Trial
Official title:
Zhongda Hospital, School of Medicine, Southeast University
Sepsis is a life-threatening disease characterized by multi-organ failure due to dysregulated
host response to infection, with high global mortality of 30-50%. One of the most important
pathophysiologic hallmarks in sepsis is vascular endothelial injury that contributes to the
severity and outcome of the syndrome. Effective treatments for endothelial cell injury in
sepsis have been lacking to improve prognosis. Endothelial pyroptosis is a vital mechanism of
vascular endothelial injury in sepsis; mitigation or abolishment of endothelial cell
pyroptosis alleviate vascular endothelial damage and improve the prognosis of sepsis mice.
Gasdermin D (GSDMD) mediated endothelial pyroptosis plays a critical role in modulating
vascular endothelial injury in sepsis.
Long non-coding RNA (lncRNA), as a class of non-coding protein RNA longer than 200 kD,
contributes to a variety of cell biological processes. The dysregulation of lncRNA results in
the occurrence and development of tumors, diabetes, sepsis and other diseases. Therefore, we
detected lncRNA and mRNA expression profile in 26 blood samples of septic patients using
Arraystar LncRNA Microarray. We found lncRNA NBR2 regulates septic endothelial pyroptosis.
To assess any correlation of pyroptosis levels with relevant endothelial cell injury
parameters and determine the prognostic value in septic patients. we measured the levels of
pyroptosis in patients admitted to the Department of Critical Care Medicine for sepsis and
investigated the correlation with related markers of endothelium injury. Furthermore, we
determined the prognostic value of pyroptosis levels for the mortality of patients with
sepsis.
We measured the levels of pyroptosis in patients admitted to the Department of Critical Care Medicine for sepsis and investigated the correlation with related markers of endothelium injury. Furthermore, we determined the prognostic value of pyroptosis levels for the mortality of patients with sepsis. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05095324 -
The Biomarker Prediction Model of Septic Risk in Infected Patients
|
||
| Completed |
NCT02714595 -
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
|
Phase 3 | |
| Completed |
NCT03644030 -
Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
|
||
| Completed |
NCT02867267 -
The Efficacy and Safety of Ta1 for Sepsis
|
Phase 3 | |
| Completed |
NCT04804306 -
Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
|
||
| Recruiting |
NCT05578196 -
Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections.
|
N/A | |
| Terminated |
NCT04117568 -
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
|
||
| Completed |
NCT03550794 -
Thiamine as a Renal Protective Agent in Septic Shock
|
Phase 2 | |
| Completed |
NCT04332861 -
Evaluation of Infection in Obstructing Urolithiasis
|
||
| Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
| Enrolling by invitation |
NCT05052203 -
Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
|
||
| Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
| Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
| Completed |
NCT03258684 -
Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock
|
N/A | |
| Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
| Completed |
NCT05018546 -
Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery
|
N/A | |
| Completed |
NCT03295825 -
Heparin Binding Protein in Early Sepsis Diagnosis
|
N/A | |
| Not yet recruiting |
NCT06045130 -
PUFAs in Preterm Infants
|
||
| Not yet recruiting |
NCT05361135 -
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
|
N/A | |
| Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 |